Compare IDEXX Laboratories, Inc. (IDXX) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs PulteGroup, Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $558.25 (market cap $44.48B), while PulteGroup, Inc. trades at $123.31 (market cap $23.46B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and PulteGroup, Inc. pays a 0.84% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | PHM | |
|---|---|---|
Market Cap | $44.48B | $23.46B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $142.56 |
52-Week Low | $520.87 | $108.65 |
Enterprise Value | $45.38B | $23.42B |
Dividend Yield | — | 0.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
PulteGroup (PHM) trades at $123.12, down 2.35% today, with a bullish technical signal from moving averages but neutral oscillators. The stock shows solid fundamentals with a P/E of 12.19, net income margin of 12.14%, and positive cash flow trends, though recent earnings missed expectations in two of the last three quarters. Recent news highlights mixed investor sentiment amid mortgage rate concerns and new community developments, with a dividend payment scheduled for July 2, 2026.
Outlook is cautiously optimistic with a consensus price target of $146.50, implying 19% upside, supported by strong institutional holdings and a GF Score of 93. Key risks include high mortgage rates pressuring margins and volatile housing demand. The stock's current level near the analyst low target of $123.00 suggests potential support, but earnings performance in the upcoming Q2 report will be critical for momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
